Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Crossover Study in Healthy Subjects to Evaluate the Effect of Food and Acid Reducing Agent(s) on the Pharmacokinetics of Capivasertib

Next Previous
Search
Trial Profile

An Open-label, Randomized, Crossover Study in Healthy Subjects to Evaluate the Effect of Food and Acid Reducing Agent(s) on the Pharmacokinetics of Capivasertib

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capivasertib (Primary) ; Rabeprazole
  • Indications Breast cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 16 Jun 2023 Results assessing the effect of food and an acid-reducing agent (rabeprazole) on the pharmacokinetics (PK) and safety of capivasertib, published in the British Journal of Clinical Pharmacology.
  • 06 May 2022 Status changed from active, no longer recruiting to completed.
  • 31 Mar 2022 Planned End Date changed from 1 Apr 2022 to 29 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top